Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial.

Trial Profile

Treating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled Trial.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2012

At a glance

  • Drugs Ramelteon (Primary)
  • Indications Dyssomnias
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 05 May 2010 Official Title amended as reported by ClinicalTrials.gov.
    • 27 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top